FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

vasimigton	, D.O.	200-0	

Check this box if no longer subject to							
Section 16. Form 4 or Form 5							
obligations may continue. See							
Instruction 1(b).							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPR	OVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

1. Name and Address of Reporting Person* HARRIS JOHN DAVID					2. Issuer Name and Ticker or Trading Symbol CYTORI THERAPEUTICS, INC. [CYTX]							[Ch	elationship o eck all applica Director	able)) Perso	on(s) to Issu 10% Ov Other (s	/ner
(Last) 3020 CA	(F LLAN RD	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/04/2016								below)	and GM Cell Therapy		респу	
(Street)	EGO C.	A	92121	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line) 【 Form fil	Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/Date)				te	Execution Date,		Code (Instr.			5. Amount Securities Beneficia Owned For Reported	s Form Illy (D) o ollowing (I) (II		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)			,iiisti. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) f ive	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s lly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	UII(S)		
Employee Stock Option	(1)	01/04/2016		A		349,830		(2)	01	1/04/2026	Common Stock	349,830	\$0	684,83	80	D	

Explanation of Responses:

- 1. The reporting person received an NQ stock option granted under the Corporation's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised shall be the closing sale price of the Corporation's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price is \$0.1872.
- 2. Twenty five percent (25%) of the option shares shall vest on January 4, 2017 with the remaining option shares vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ Jeremy B. Hayden, Attorney in Fact

01/04/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.